Evidence map›Paper›PMID 40875119›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2025

SUMO-Activated Target Traps (SATTs) for the Identification of Specific SUMOylated Proteins for an E3 Ligase of Interest.

Daniel Salas-Lloret, Román González-Prieto

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Ubiquitin and SUMO pathways in DNA replication and replication-coupled repair.Critical reviews in biochemistry and molecular biology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Daniel Salas-LloretH12O-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. dsalas@cnio.es.
Román González-PrietoAndalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), Universidad de Sevilla-CSIC-Universidad Pablo de Olavide, Sevilla, Spain. roman.gonzalez@cabimer.es.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SUMOylation is a dynamic and reversible post-translational modification that occurs on acceptor lysines of substrate proteins. SUMO is conjugated via a dedicated enzymatic cascade of E1-E2-E3 enzymes, where the E3 confers substrate specificity. More than 6500 SUMO2/3 target proteins have been identified by mass spectrometry-based proteomics with important regulatory roles, predominantly in nuclear processes. However, although there are fewer than a dozen bona fide E3 ligases, matching an E3 ligase to the modification of specific SUMOylated proteins remains challenging. Here, we introduce SATTs (SUMO-activated target traps) to directly trap substrates of a SUMO E3 ligase of interest (E3OI) and subsequently identify them by LC-MS/MS analysis. The SATT methodology consists of a linear fusion of your E3OI with either SUMO1 or SUMO2/3 flanked by two 10xHis tags. This strategy allows the E3OI to conjugate the fused SUMO moiety to target proteins, forming E3OI-SUMO-target complexes, which can be Ni-NTA purified and detected by LC-MS/MS. A detailed description of the methodology is provided in this chapter, including a discussion of potential pitfalls and specific recommendations.

Indexed as

ProteomicsSmall Ubiquitin-Related Modifier ProteinsSUMO-1 ProteinSumoylationUbiquitin-Protein LigasesChromatography, LiquidHumansProtein Processing, Post-TranslationalSubstrate SpecificityTandem Mass SpectrometryUbiquitinsSmall Ubiquitin-Related Modifier ProteinsSUMO-1 ProteinSUMO2 protein, humanSUMO3 protein, humanUbiquitin-Protein LigasesUbiquitinsE3 ligasesMass spectrometryProteomicsSATTsSUMO

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.